GlassScriptPhysician profile
Hannah Vise Lax
NPI 1750719605
$1,648.73
in general payments reported to CMS, 2019-2025
22 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $424 · 2023: $446 · 2024: $343 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.74 | 2021-2024 | |
| Novo Nordisk INC | $444.73 | 2021-2025 | Wegovy |
| Amgen INC. | $109.89 | 2022-2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $71.82 | 2023-2024 | Rexulti |
| Teleflex LLC | $71.73 | 2025 | Barrigel, Urolift |
| Pfizer INC. | $58.61 | 2021-2024 | |
| Biogen, INC. | $56.47 | 2025 | Zurzuvae |
| Lilly USA, LLC | $55.20 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Dexcom, INC. | $47.97 | 2021-2022 | |
| Janssen Biotech, INC. | $42.97 | 2025 | Erleada |
| Abbott Laboratories | $24.56 | 2021 | |
| Glaxosmithkline, LLC. | $23.13 | 2024 | Trelegy Ellipta, Arexvy |
| Shield Therapeutics INC | $22.43 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.93 | 2021 | |
| Astellas Pharma US INC | $18.63 | 2025 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15.54 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.48 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.43 | 2022 | |
| Daiichi Sankyo INC. | $15.40 | 2025 | Enhertu |
| Olympus America INC. | $14.11 | 2025 | Itind System |
| Astrazeneca Pharmaceuticals LP | $14.00 | 2023 | Breztri |
| Novartis Pharmaceuticals Corporation | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Lax listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.